Current Funding Opportunities

Click here to visit the NCI grant site.

Use your device's search function to find a specific disease or funding source. 



Multiple Myeloma Research Foundation

The Multiple Myeloma Research Foundation (MMRF) seeks proposals for the MMRF 2018 Research Fellow Award Program, an initiative supporting researchers at the post-doctorate/medical fellow or junior faculty levels working under the supervision or guidance of a research mentor in the multiple myeloma field. The goal of this initiative is to help support young investigators to begin their studies in the field of multiple myeloma while advancing the understanding of myeloma disease biology, treatment and drug resistance.  Proposals may request up to $75,000 for one (1) year.

Application Deadline: May 25, 2018



The Mark Foundation for Cancer Research Emerging Leader Awards

These signature three-year academic grants totaling $750,000 will provide support to early career investigators conducting high-risk, high-impact cancer research.

Letters of Intent Due: June 4, 2018


Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R01 - Clinical Trial Not Allowed)

The purpose of this FOA is to promote epidemiologic research investigating novel and innovative hypotheses on emerging risk factors (biological, environmental, and social) and their interplay with established risk factors (e.g., viral hepatitis) associated with the development of liver cancer (hepatocellular carcinoma and other histological subtypes) in the United States.

Application Deadline: June 5, 2018


NIH Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy-R01

This FOA seeks research project (R01) grant applications describing projects that integrate imaging and fluid-based tumor monitoring (liquid biopsy) assays during cancer therapy in patients to determine the optimal use of those modalities.

Application Deadline: June 5, 2018

Learn more about NIH funding for fluid-based tumor monitoring>>


NIH End-of-Life and Palliative Care Health Literacy: Improving Outcomes in Serious, Advanced Illness-R01/R21

This FOA seeks to stimulate research focused on identification of the key barriers to effective end-of-life and palliative care (EOLPC) health literacy in diverse settings and populations.

Application Deadline: June 5, 2018

Learn More about NIH end-of-life funding>>


NIH Biology of Lung, and Head and Neck Preneoplasias-R01/R21

This Funding Opportunity Announcement (FOA) seeks applications investigating mechanistic and biological aspects of preneoplasia leading to lung, and head and neck (HN) cancers.

Application Deadline: June 5, 2018

Learn more about NIH funding for lung and head and neck preneoplasias>>


Alex’s Lemonade Stand Psychosocial Grants (LOI June 11, 2018)

ALSF is committed to addressing the psychosocial and behavioral health outcomes for children diagnosed with cancer and their families. These Grants fill a direct need for research funding by supporting studies that aim to explain and/or improve psychosocial outcomes of those affected by childhood cancer. 

Letters of Intent Due: June 11, 2018  



NIH Food Specific Molecular Profiles and Biomarkers of Food and Nutrient Intake, and Dietary Exposure (R01 Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to promote research on food specific molecular signatures and biomarkers of dietary consumption and to promote collaborative interactions among NIH and the United States Department of Agriculture - National Institute on Food Safety (USDA-NIFA) supported nutrition researchers.

Application Deadline: June 11, 2018

Learn More about grant from the NIH and USDA>>

NIH Food Specific Molecular Profiles and Biomarkers of Food and Nutrient Intake, and Dietary Exposure-R01

The purpose of this FOA is to promote research on food specific molecular signatures and biomarkers of dietary consumption and to promote collaborative interactions  among NIH and the USDA-NIFA supported nutrition researchers.

Application Deadline: June 11, 2018

Learn More about NIH funding for dietary exposure>>

U.S. Tobacco Control Policies to Reduce Health Disparities (R21 Clinical Trial Optional)

The purpose of this FOA is to support observational or intervention research focused on reducing health disparities in tobacco use in the United States. Specifically, this FOA is intended to stimulate scientific inquiry focused on innovative tobacco control policies. Applicants may propose projects in which the primary outcome of interest is on reducing tobacco use health disparities in vulnerable populations by utilizing tobacco prevention and control strategies. The long-term goal of this FOA is to reduce health disparities in health outcomes thereby reducing the excess disease burden of tobacco use within these groups. Applicants submitting applications related to health economics are encouraged to consult NOT-OD-16-025 to ensure that applications align with NIH mission priorities in health economics research.

Application Deadline: June 13, 2018

 
U.S. Tobacco Control Policies to Reduce Health Disparities (R01 Clinical Trial Optional)

The purpose of this FOA is to support observational or intervention research focused on reducing cancer health disparities in tobacco use in the United States. Specifically, this FOA is intended to stimulate scientific inquiry focused on innovative tobacco control policies. Applicants may propose projects in which the primary outcome of interest is on reducing tobacco use cancer health disparities in vulnerable populations by utilizing tobacco prevention and control strategies. The long-term goal of this FOA is to reduce cancer health disparities in health outcomes thereby reducing the excess disease burden of tobacco use within these groups. Applicants submitting applications related to health economics are encouraged to consult NOT-OD-16-025 to ensure that the research projects align with NIH mission priorities in health economics research.

Application Deadline: June 13, 2018



NIH Exploratory Grants in Cancer Epidemiology and Genomics Research-R21

This FOA invites applications for research on cancer epidemiology, genomics, and risk assessment.

Application Deadline: June 16, 2018

Learn More about NIH grant in epidemiology>>

NIH Diet and Physical Activity Assessment Methodology-R21

This Funding Opportunity Announcement (FOA) encourages innovative research to enhance the quality of measurements of dietary intake and physical activity.

Application Deadline: June 16, 2018

Learn More about NIH funding for diet and activity>> 


Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R21 - Clinical Trial Not Allowed)

The purpose of this FOA is to promote epidemiologic research investigating novel and innovative hypotheses on emerging risk factors (biological, environmental, and social) and their interplay with established risk factors (e.g., viral hepatitis) associated with the development of liver cancer (hepatocellular carcinoma and other histological subtypes) in the United States.

Application Deadline: June 16, 2018



NIH Exploratory Grant Award to Promote Workforce Diversity in Basic Cancer Research-R21

This FOA represents the continuation of an NCI program to enhance  the diversity of the pool of the cancer research workforce.

Application Deadline: June 19, 2018

Learn More about NIH funding for workforce diversity>>
 
PREVENT Cancer Preclinical Drug Development Program RFP

The NCI has issued a RFP to support the PREVENT Cancer Preclinical Drug Development Program: Preclinical Services for Biopharmaceutical Product Development and Manufacturing, Toxicology and Pharmacology Testing. The overall objective of the current acquisition is to provide a structured approach to drug and vaccine development, from discovery to the clinic.

Application Deadline: June 21, 2018


Research Answers to National Cancer Institute's (NCI) Provocative Questions (R01 Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to support research projects designed to solve specific problems and paradoxes in cancer research identified by the National Cancer Institute (NCI) Provocative Questions initiative. These problems and paradoxes phrased as questions are not intended to represent the full range of NCI's priorities in cancer research. Rather, they are meant to challenge cancer researchers to think about and elucidate specific problems in key areas of cancer research that are deemed important but have not received sufficient attention.

ApplicationDeadline: June 29, 2018



 
Research Answers to National Cancer Institute's (NCI) Provocative Questions (R21 Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to support research projects designed to solve specific problems and paradoxes in cancer research identified by the National Cancer Institute (NCI) Provocative Questions initiative. These problems and paradoxes phrased as questions are not intended to represent the full range of NCI's priorities in cancer research. Rather, they are meant to challenge cancer researchers to think about and elucidate specific problems in key areas of cancer research that are deemed important but have not received sufficient attention.

Application  Deadline:  June 29, 2018


Robert E. Leet and Clara Guthrie Patterson Trust Mentored Research Award: Clinical, Health Services and Policy Research

This Trust was created in 1980 for the advancement of  medical science, particularly research “relating to human diseases,  their causes and relief.” Two-year Awards of $90,000 ($45,000 per year)  will be awarded to Applicants working in Connecticut, New Jersey and  Rhode Island.

Application Deadline: July 3, 2018

Learn more about the Robert E. Leet Mentored Research Award>>

NIH Early-life Factors and Cancer Development Later in Life-R01 

The purpose of this FOA is to stimulate research focused on the role of early-life factors (maternal-paternal, in utero, birth and infancy, puberty, adolescence, and young adult years) in cancer development later in life. 

Application Deadline: July 5, 2018



NIH Core Infrastructure and Methodological Research for Cancer Epidemiology Cohorts (U01) 

Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) encourages grant applications for support of the core functions of Cancer Epidemiology Cohorts (CECs), as well as methodological research.

Application Deadline: July 5, 2018



Damon Runyon-Rachleff Innovation Award 

Designed to provide support for the next generation of exceptionally creative thinkers with “high-risk/high-reward” ideas that have the potential to significantly impact our understanding of and/or approaches to the prevention, diagnosis or treatment of cancer. 

Application Deadline: July 6, 2018


Innovative Basic Research on Adducts in Cancer Risk Identification and Prevention (R21 Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA), encourages research projects focused on adducts to cellular macromolecules as indicators of exposures to cancer risk factors relevant to human populations. The priority is on projects that will focus on adductomic approaches, i.e., address some aspects of the totality of adducts. These projects should explore the basic aspects of adducts/adductomics that may have a potential utility in cancer detection, cancer prevention, and/or assessing cancer risks. The projects should be relevant to adducts in humans and human populations but may be conducted using various model systems (e.g., cultured cells, animals, etc.). The use of human biospecimens is encouraged and expected if appropriate but not required. In well-justified cases, innovative studies using the adductomic approaches in the context of cancer etiology and/or gene-environment interaction research may also be appropriate. NIEHS may support projects with a focus on innovative technology and method development.  

Application Deadline: July 11, 2018


 
Innovative Basic Research on Adducts in Cancer Risk Identification and Prevention (R01 Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA), encourages research projects focused on adducts to cellular macromolecules as indicators of exposures to cancer risk factors relevant to human populations. The priority is on projects that will focus on adductomic approaches, i.e., address some aspects of the totality of adducts. These projects should explore the basic aspects of adducts/adductomics that may have a potential utility in cancer detection, cancer prevention, and/or assessing cancer risks. The projects should be relevant to adducts in humans and human populations but may be conducted using various model systems (e.g., cultured cells, animals, etc.). The use of human biospecimens is encouraged and expected if appropriate but not required. In well-justified cases, innovative studies using the adductomic approaches in the context of cancer etiology and/or gene-environment interaction research may also be appropriate. NIEHS may support projects with a focus on innovative technology and method development. 

Application Deadline:  July 11, 2018

Learn More>>

Exploratory/Developmental Clinical Research Grants in Obesity- R21

This FOA encourages research grant applications from institutions/organizations that propose to conduct exploratory/developmental clinical studies that will accelerate the development of effective interventions for prevention or treatment of overweight or obesity in adults and/or children.

Application Deadline: July 16, 2018



NIH Fogarty HIV Research Training Program for Low-and Middle-Income Country Institutions-D43

The purpose of this FOA is to encourage applications for research training programs to strengthen the scientific capacity of institutions in low- and middle-income countries (LMICs) to conduct HIV research relevant to the evolving HIV epidemic in their country.

Deadline for Application: August 23, 2018

Defense Health Program: Department of Defense Ovarian Cancer Research Program - Anticipated Funding Opportunities for Fiscal Year 2018 (FY18)


*Although funds have not been appropriated for the FY18 Department of Defense Ovarian Cancer Research Program (OCRP), the OCRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY18 funding opportunities.

This pre-announcement should not be construed as an obligation by the Government, and funding of research projects received in response to these Program Announcements is contingent on the availability of federal funds appropriated for the OCRP. 

As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA) J9, Research and Development Directorate, manages the Defense Health Program Research, Development, Test, and Evaluation appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP). The mission of the OCRP is to support patient-centered research to prevent, detect, treat, and cure ovarian cancer to enhance the health and well-being of Service members, Veterans, retirees, their family members, and all women impacted by this disease.

Clinical Development Award
• Must be an independent investigator at or above the level of Assistant Professor (or equivalent).
• Supports the translation of promising preclinical findings into products for clinical applications, including prevention, detection, diagnosis, treatment, or quality of life.
• Near-term impact is expected.
• Preclinical studies in animals are not allowed.
• Small-scale clinical trials (Phase 0, Phase 1, Pilot), studies enriching a clinical trial, and projects related to or associated with ongoing or completed clinical trials are allowed.
• Preliminary data are required.
Optional Nested Early-Career Investigator (ECI): Applications proposing clinical trials and having an ECI that meets the criteria outlined in the Program Announcement/Funding Opportunity will qualify for a higher level of funding.
• Submission of a Letter of Intent is required prior to full application submission.
• Maximum funding of $600,000 for direct costs (plus indirect costs).
• With ECI option the maximum funding is $800,000 for direct costs (plus indirect costs).
• Maximum period of performance is 3 years.

Letter of Intent Due: July 25, 2018

Omics Consortium Development Award
• Must be an independent investigator at the Associate Professor level or above (or equivalent)
• Supports a multi-institutional research effort conducted by leading cancer researchers and advocates that focuses on the origin of ovarian cancer, with an emphasis on risk stratification, screening and early detection.
• Funds support assembling consortium members and laying the groundwork for the research project, including proof of concept.
• Ovarian cancer advocate(s) are required on the research team.
• Funded applicants will be eligible to compete for the consortium award, which will support the execution of the full research project and is anticipated to be offered in FY20, pending availability of funds.
• Submission of a Letter of Intent is required prior to full application submission
• Maximum funding of $400,000 for direct costs (plus indirect costs).
• Period of performance not to exceed 2 years. 

Letter of Intent Due: July 25, 2018

Investigator-Initiated Research Award
• Must be an independent investigator at or above the level of Assistant Professor (or equivalent).
• Supports meritorious basic and clinically oriented research in ovarian cancer.
• Impact is an important review criterion.
• Preliminary data are required.
• Clinical trials are not allowed.
• Pre-application is required; application is by invitation only.
• Maximum funding of $450,000 for direct costs (plus indirect costs).
• Maximum period of performance is 3 years. 

Pre-application Due: May 30, 2018

Ovarian Cancer Academy Award – Early-Career Investigator
• Must be within 3 years of his/her last postdoctoral research position (Ph.D.) or clinical fellowship (M.D.), or equivalent as of the full application submission deadline. A letter attesting to eligibility is required.
• Supports the addition of new ECIs to the unique, interactive virtual academy that provides intensive mentoring, national networking, and a peer group for junior faculty.
• ECIs whose ability to commit to conducting ovarian cancer research is limited by lack of resources or other overwhelming obstacles are encouraged to apply.
• A Designated Mentor who is an experienced ovarian cancer researcher with ovarian cancer funding is required.
• A Designated Mentor may only mentor one ECI candidate.
• The Designated Mentor is not required to be at the same institution as the ECI.
• Preliminary data are required.
• Clinical trials are allowed.
• Submission of a Letter of Intent is required prior to full application submission.
• Maximum funding of $725,000 for direct costs (plus indirect costs).
• Maximum period of performance is 4 years. 

Letter of Intent: July 25, 2018

Pilot Award
• Investigators at or above the postdoctoral level (or equivalent).
• Supports innovative, high-risk/high-reward research that could ultimately lead to critical discoveries or major advancements that will drive the field of ovarian cancer research forward.
• Innovation and Impact are important review criteria.
• Goal is to develop preliminary data; thus, preliminary data are not required, but are allowed.
• Clinical trials are not allowed.
• Pre-application is required and blinded; application submission is by invitation only.
• Maximum funding of $250,000 for direct costs (plus indirect costs).
• Maximum period of performance is 2 years. 

Pre-application Deadline: May 30, 2018

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

Applications must be submitted through the Federal Government’s single-entry portal, Grants.gov. Submission deadlines are not available until the Program Announcements are released. For email notification when Program Announcements are released, go to the CDMRP website (http://cdmrp.army.mil) and select Subscribe to Funding Opportunities & Program Communications. For more information about the OCRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

The Yale Cancer Center Internal Grant Program aims to provide funds for innovative, high quality start-up cancer research programs and provide new investigators with experience and guidance in the grant-writing process. 

The criteria for funding is high quality, innovative cancer research with a likelihood to result in NIH-funded cancer research and encourage collaborations within YCC. Grant competitions will be announced in DirectConnect and will undergo an anonymous NIH-style peer review with written reviews provided to applicants.  


Pew-Stewart Scholars Program for Cancer Research

Yale Cancer Center is pleased to announce the internal competition for the Pew-Stewart Scholars for Cancer Research Program.

The Pew-Stewart Scholars for Cancer Research Program supports assistant professors of outstanding promise in science relevant to the advancement of a cure for cancer.

Deadline for Applications: June 5, 2018



Gabrielle's Angel Foundation for Cancer Research Grants

The Foundation funds cutting-edge research in the fields of leukemia, lymphoma, and related cancers of the blood. Funds support promising scientists who are applying novel and state-of-the-art techniques to address fundamental problems in their genesis and treatment.

Internal Deadline: June 11, 2018



Yale Cancer Innovation Awards

YCC is committed to promoting innovative new approaches to cancer treatment and prevention. In collaboration with an anonymous donor, we are proud to announce an empowering new research award program in cancer research.

YCC is requesting individual or team proposals for projects that have direct relevance to cancer research. We seek projects with the potential to significantly impact our understanding of and/or approaches to the prevention, diagnosis, or treatment of cancer. Ultimately, we aim to advance proposals that will solve today’s most challenging problems in cancer research and care.

Application Deadline: June 18, 2018

Learn more about the Yale Innovation award>>


P rogram in Innovative Therapeutics for Connecticut's Health (PITCH) 
 
With a grant from the State of Connecticut’s Bioscience Innovation Fund, this three-year, $10 million-dollar program, provides translational research resources to generate prototype therapeutics that address unmet clinical needs. Contact francine.carland@yale.edu for more information. 
 
Application Deadline: July 15, 2018